Preclinical Dosing Overview
Tirzepatide's extended half-life (~5 days) supports once-weekly or twice-weekly dosing in rodent research models. Published preclinical pharmacology data provides reference ranges for common study designs.
Published Rodent Dosing Reference
Mouse (DIO/ob/ob Models)
- Acute GLP-1R studies: 0.03–3 nmol/kg
- Chronic weight studies: 0.1–1 mg/kg twice weekly
- Insulin secretion studies: 1–100 nM in vitro
Rat
- Glucose tolerance: 0.01–0.3 mg/kg
- Chronic metabolic: 0.1–1 mg/kg once weekly
- Cardiovascular models: 0.3 mg/kg once weekly
Concentration Calculations
15mg Vial
| 3 mL | 5 mg/mL |
| 5 mL | 3 mg/mL |
| 15 mL | 1 mg/mL |
30mg Vial
| 6 mL | 5 mg/mL |
| 10 mL | 3 mg/mL |
| 30 mL | 1 mg/mL |
60mg Vial
| 12 mL | 5 mg/mL |
| 20 mL | 3 mg/mL |
| 60 mL | 1 mg/mL |
Study Design Considerations
- Model selection: DIO mice for obesity; ob/ob for severe obesity; ZDF rats for T2D comorbidity
- Controls: Vehicle, pair-fed, semaglutide comparator arm
- Dose escalation: Not always required in rodents; can start at therapeutic equivalent
- Duration: Minimum 8 weeks for steady-state metabolic effects; 16+ weeks for full body composition changes
- Endpoints: Body weight, body composition (NMR/DEXA), glucose/insulin/lipids, tissue histology, organ weights
For research purposes only. Not for human administration.Research Disclaimer. The information contained in this guide is for educational and scientific informational purposes only. It does not constitute medical advice, diagnosis, or treatment. All products referenced are intended for laboratory research use only — not for human consumption or therapeutic administration. Consult a licensed healthcare professional for any medical decisions.